The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
08.05.2022The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
08.05.2022The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
We were delighted to welcome CEO National Resilience Inc. Rahul Singhvi who visited our labs and office space.
04.05.2022Mark Kotter talks about the benefits of human cells for researchers, and how they can shape the future of drug development.
21.04.2022Leading experts across academia and industry share their thoughts into the challenges of in vitro cell models.
28.03.2022²»Á¼Ñо¿Ëù CEO Dr Mark Kotter interviewed by Fiona Mischel on the Built with Biology Podcast.
25.03.2022They ask about reprogramming cells and how the company is aiming to develop cell therapies.
17.03.2022The article offers 6 tips for successful pharma startups.
01.03.2022This case study delves into the company story, technology and vision.
16.02.2022Read the TechRound feature on Cambridge University spin-outs, including ²»Á¼Ñо¿Ëù. Learn about the origins of our opti-oxâ„¢ technolog...
10.02.2022